MAS Balanced
BalancedBalanced Sustainability Rated5yr Return
5.7%
3yr Return
11.8%
1yr Return
10.3%
3m Return
2.00%
Total Fee
0.99%
Fund Size
$426.0M
The WealthWatch View
A single fixed interest fund accounts for more than a fifth of this $426 million balanced portfolio, with the Hunter Global Fixed Interest Fund sitting as the largest holding at 21.6%. That concentration sets the tone for a fund that leans heavily on bonds, with 36% in fixed interest overall and just 61% in growth assets, placing it at the conservative end of the balanced category. Total fees come to 0.99%, comprising a 0.85% management charge and 0.13% in other costs.
The fund returned 10.3% over the past year, placing 8th in its category, and has delivered 11.8% annually over three years, sitting 15th. Over five years the return drops to 5.7%, ranking 12th. The equity allocation favours international shares at 41.5%, with Australasian shares at 18.1%. Within that, the fund holds a clear tilt toward New Zealand stocks, with Fisher & Paykel Healthcare, Infratil and Auckland Airport all featuring prominently. Among international names, NVIDIA leads at 2.0%, followed by Apple, Alphabet and Micron Technology, signalling exposure to US tech.
Medical Assurance Society runs this fund with a bond-heavy structure and a home bias in its equity sleeve. The result is a balanced fund that sits closer to defensive territory than many of its peers.
General information only, not financial advice. Past performance is not a reliable indicator of future results.
Asset Allocation
Top Holdings
The fund's largest investments
Hunter Global Fixed Interest Fund
Bonds · NZ
Custody Call Account - NZD
Cash · NZ
Fisher & Paykel Healthcare Ltd
Shares · NZ
Infratil Ltd
Shares · NZ
NVIDIA Corp
Shares · US
Apple Inc
Shares · US
Auckland International Airport Ltd
Shares · NZ
Alphabet Inc Class A
Shares · US
Micron Technology Inc
Shares · US
Meridian Energy Limited
Shares · NZ
Historical Returns
3 Month
2.00%
1 Year
10.3%
3 Year
11.8%
annualised
5 Year
5.7%
annualised
10 Year
7.0%
Since Inception
—%
annualised
Fees
Category Rankings
Ranked within Balanced funds
Risk Level
Medium
Fund Managers
Daniel Mead
Head of Investment
2 years, 11 months in role
Rickey Ward
Head of Investment Strategy & Research, JBWere
1 year, 2 months in role
Brendan O’Donovan
Chair Investment Committee
8 years, 12 months in role
Hayden Griffiths
Head of Asset Allocation, JBWere
30 years, 2 months in role
Phil Borkin
Senior Strategist, JBWere
7 years, 6 months in role
Ready to invest?
Talk to a licensed adviser about this fund.
Get Matched